Advertisement
Collaboration › Details
Hookipa–Leerink: investor conference, 201802 supply service Hookipa to attend Leerink Partners Global Healthcare Conference 2018
Period | 2018-02-14 � 2018-02-15 | |
Region | New York, NY | |
Country | United States (USA) | |
Partner, 1st | Hookipa Biotech AG | |
Group | Hookipa (Group) | |
Partner, 2nd | Leerink Partners LLC [old] | |
Today | Leerink Partners (Group) | |
Group | Leerink Partners (Group) | |
Product | Leerink Partners Annual Global Healthcare Conference 2018 New York | |
Product 2 | Vaxwave® technology | |
Person | Aldag, Jörn (Hookipa Biotech 201606– CEO before Uniqure/AMT + Evotec + MAN GHH) | |
Person 2 | Matushansky, Igor (Hookipa Biotech 201802 CMO) | |
Hookipa Biotech AG. (2/6/18). "Press Release: Hookipa Biotech to Attend the Leerink Partners 7th Annual Global Healthcare Conference". Vienna.
Hookipa Biotech AG (“Hookipa”), a clinical stage biotech company pioneering an innovative class of immune activation therapies for oncology and infectious diseases, today announced that CEO Joern Aldag and CMO Igor Matushansky will be attending the LEERINK Partners 7th Annual Global Healthcare Conference at the Lotte New York Palace Hotel in New York, USA on Wednesday, February 14th and Thursday, February 15th, 2018.
Mr. Aldag and Dr. Matushansky will participate in a series of one-on-one meetings with select institutional investors to provide an overview of the company´s strategy as well as an update on its development programs, including progress on two proof-of concept clinical trials and plan to expand its technology platform into other disease areas.
-END
About Hookipa Biotech
Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms.
Hookipa´s Vaxwave® technology presents a completely new replication-defective viral vector platform designed to overcome the limitations of current technologies. Vaxwave® is based on lymphocytic choriomeningitis virus (LCMV). In this vector the gene encoding the LCMV envelope protein, normally responsible for virus entry into target cells, has been deleted and replaced with an antigen of interest. The resulting vectors infect dendritic cells and stimulate very potent and long-lasting immune response, however they cannot replicate and are therefore non-pathogenic and inherently safe.
Hookipa’s TheraT® platform is based on an attenuated replicating arenavirus and is capable of eliciting the most potent T cell responses - a crucial step in treating patients with aggressive cancers. Significant pre-clinical data demonstrates that TheraT® is a powerful modality capable of turning “cold tumors hot” which should result in an additional layer of efficacy in the fight against solid tumors. Specifically, TheraT® has proven to be safe in animals as well as capable of eliciting uniquely potent antigen-specific CD8+ cytotoxic T cell responses and strong tumor control in mice. The first clinical trial with HB-201 targeting human papilloma virus-induced head and neck cancer is currently being prepared. This immuno-oncology technology is further being leveraged to target tumor self-antigens or shared neoantigens.
Issued for and on behalf of Hookipa Biotech AG by Instinctif Partners.
For further information please contact:
At the Company
Marine Popoff
Communications Analyst
Hookipa Biotech AG
Mpopoff@Hookipabiotech.com
Media enquiries
Sue Charles/ Ashley Tapp
Instinctif Partners
hookipa@instinctif.com
+44 (0)20 7866 7923
Record changed: 2018-12-12 |
Advertisement
More documents for Hookipa (Group)
- [1] Hookipa Pharma Inc.. (1/29/24). "Press Release: Hookipa Pharma Provides Update on Business Priorities and Oncology Partnership Programs". New York, NY & Vienna....
- [2] Hookipa Pharma Inc.. (12/21/23). "Press Release: Hookipa Pharma Announces $21.25 Million Equity Investment from Gilead Sciences". New York, NY & Vienna....
- [3] Hookipa Pharma Inc.. (5/31/23). "Press Release: Hookipa Pharma Announces Pricing of $50.0 Million Public Offering of Common Stock and Non-Voting Convertible Preferred Stock". New York, NY & Vienna....
- [4] Hookipa Pharma Inc.. (2/13/23). "Press Release: Hookipa Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers". New York, NY & Vienna....
- [5] Hookipa Pharma Inc.. (1/4/23). "Press Release: Hookipa Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine". New York, NY & Vienna....
- [6] Hookipa Pharma Inc.. (10/20/22). "Press Release: Hookipa Announces Strategic Collaboration and License Agreement with Roche to Develop Novel Arenaviral Immunotherapy for KRAS-mutated Cancers". New York, NY & Vienna....
- [7] Hookipa Pharma Inc.. (10/6/21). "Press Release: Groundbreaking Ceremony for Hookpia’s New Production Site". Vienna....
- [8] Genespire S.r.l.. (7/30/20). "Press Release: Genespire Appoints Jörn Aldag as Chairman of the Board of Directors". Milan....
- [9] Hookipa Pharma Inc.. (7/11/19). "Press Release: Hookipa Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers". New York, NY & Vienna....
- [10] Hookipa Pharma Inc.. (5/8/19). "Press Release: Hookipa Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead". New York, NY & Vienna....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top